Abstract Details

Title Evaluating the implementation of a pharmacist-driven epilepsy education and adherence program

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-002

Objective Evaluate the feasibility and impact of implementing a pharmacist-driven Medication Therapy Management (MTM) service for patients with epilepsy to improve adherence, self-efficacy, and disease morbidity.

Background Medication adherence rates as low as 30-50% have been reported for patients with epilepsy, which may result in limited seizure control, decreased quality of life, and increased morbidity. Pharmacist involvement in chronic disease state management through MTM services can improve patient outcomes. Several epilepsy education programs have shown improvement in epilepsy self-management; however, limited data is available to justify the value of pharmacist-led interventions.

Design/Methods

This single-center, prospective cohort study included patients at least 18 years old diagnosed with epilepsy, established at the William S Middleton VA Epilepsy Clinic (Epilepsy Center of Excellence) , and with functional capacity as confirmed by their healthcare provider. All patients provided written informed consent. A study pharmacist scheduled and conducted five telephone encounters to review educational modules: Epilepsy 101, Medication Therapy Review, Disease Management Support, Medication Action Plan, and Follow-up Pharmacotherapy Consultation. Feasibility of service implementation was determined through rate of module completion and time to complete the modules. Clinical outcomes from baseline to three months post-intervention included: Epilepsy Self-Efficacy Scale (ESES), the Epilepsy Self-Management Scale (ESMS), Patient Weighted Quality of Life in Epilepsy (QOLIE-10-P), Generalized Anxiety Disorder-7 (GAD-7), and Neurological Disorders Depression Inventory in Epilepsy (NDDI-E).

Results At time of interim analysis, 14/18 (78%) enrolled patients completed the educational series. Ten patients (56%) required at least one module rescheduling outreach. Mean duration of education sessions was 25±9 minutes (n=72 sessions). Clinical outcomes pending study completion.

Conclusions Implementation of pharmacist-led epilepsy education via telephone encounters is feasible, especially if administrative scheduling tasks are delegated to support staff. Analysis of objective impact on patient morbidity is pending study completion and will be presented.

Authors/Disclosures
Magdalena M. Siodlak, Jr., PharmD (William S. Middleton VA) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Barry E. Gidal, PhD	Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai . Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwich. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SK life sciences . Dr. Gidal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK life science .
Robert Kotloski, MD (University of Wisconsin School of Medicine and Public Health)	The institution of Dr. Kotloski has received research support from Department of Veterans Affairs.

��ɫ��

��ɫ��